SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Closed 06-02 16:00:00 EDT

8.33

-0.74

-8.16%

盘后8.43

+0.10+1.15%

19:59 EDT

High9.00	Low8.23	Vol10.35M
Open9.00	D1 Closing9.07	Amplitude8.49%
Mkt Cap1.54B	Tradable Cap1.53B	Total Shares184.53M
T/O88.72M	T/O Rate5.63%	Tradable Shares184.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":8.33,"timestamp":1780430400000,"preClose":9.07,"halted":0,"volume":10354635,"hourTrading":{"tag":"盘后","latestPrice":8.4261,"preClose":8.33,"latestTime":"19:59 EDT","volume":200724,"amount":1695195.9372,"timestamp":1780444785197,"change":0.0961,"changeRate":0.011537,"amplitude":0.032305},"delay":0,"changeRate":-0.08158765159867698,"floatShares":184000000,"shares":184532574,"eps":-0.226189,"marketStatus":"Closed","change":-0.74,"latestTime":"06-02 16:00:00 EDT","open":9,"high":9,"low":8.23,"amount":88724176.66534501,"amplitude":0.084895,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.226189,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780473600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.07,"preHourTrading":{"tag":"盘前","latestPrice":9.01,"preClose":9.07,"latestTime":"09:29 EDT","volume":44785,"amount":405972.039135,"timestamp":1780406999999,"change":-0.06,"changeRate":-0.006615,"amplitude":0.034179},"postHourTrading":{"tag":"盘后","latestPrice":8.4261,"preClose":8.33,"latestTime":"19:59 EDT","volume":200724,"amount":1695195.9372,"timestamp":1780444785197,"change":0.0961,"changeRate":0.011537,"amplitude":0.032305},"volumeRatio":0.841981,"optionData":{"bulkOrders":[{"symbol":"SLS","call":false,"expireDate":1784260800000,"strike":"10.0","timestamp":1780419884976,"price":3.1,"volume":1412,"amount":437720,"type":"-"},{"symbol":"SLS","call":true,"expireDate":1781755200000,"strike":"10.0","timestamp":1780412443542,"price":0.75,"volume":1100,"amount":82500,"type":"*"}]},"impliedVol":1.9229,"impliedVolPercentile":0.8765},"requestUrl":"/m/hq/s/SLS/wiki","defaultTab":"wiki","newsList":[{"id":"2640948033","title":"Sellas Life Sciences gets about $28.7 million from warrant exercises in April-May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948033","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948033?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:34","pubTimestamp":1780403641,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences received about $28.7 million in April–May 2026 from exercises of common stock warrants.Cash and cash equivalents totaled $107.1 million as of March 31, 2026.Shares outstanding were 196,632,574 as of June 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL4sT5Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937748","title":"Why SELLAS Life Sciences Group (SLS) Is Up 19.7% After Cramer Endorsement And REGAL Trial Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937748","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640937748?lang=en_us&edition=fundamental","pubTime":"2026-06-01 16:21","pubTimestamp":1780302080,"startTime":"0","endTime":"0","summary":"In late May 2026, CNBC’s Jim Cramer highlighted SELLAS Life Sciences Group on “Mad Money,” calling the biotech a “great spec” and giving it “two thumbs up,” while investors tracked progress in its Phase 3 REGAL trial for GPS in AML patients in remission but ineligible for stem cell transplant.\nAttention is also building around SELLAS’ second AML candidate, SLS009, with upcoming topline data viewed as a potentially important catalyst for the company’s development pipeline.\nWith recent returns...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-up-197-after-cramer-en","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-up-197-after-cramer-en","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS","BK7104","BK4139","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640998777","title":"Former Sims Bear Questions SLS Earnings Outlook -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2640998777","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640998777?lang=en_us&edition=fundamental","pubTime":"2026-06-01 11:22","pubTimestamp":1780284120,"startTime":"0","endTime":"0","summary":"0322 GMT - Morgan Stanley wonders about the durability of DDR4-driven earnings growth in Sims's SLS electronics recycling division. The bank's China Semiconductors team recently turned more constructive on DDR4 memory-chip prices because of tighter supply conditions and more resilient legacy memory demand, it says. \"While this supports near-term earnings upside for SLS, we still view current earnings as pricing-sensitive and therefore unlikely to represent a clean through-cycle earnings base,\" MS says. Still, it upgrades Sims to equal weight from underweight and raises its share-price target to A$24.00 from A$15.50. It cites near-term support for SLS earnings from DDR4 prices, among other factors. Shares are up 0.9% at A$27.07. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334520","title":"Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637334520?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:40","pubTimestamp":1779464437,"startTime":"0","endTime":"0","summary":"Recent Performance Snapshot\nSELLAS Life Sciences Group (SLS) has drawn attention after a sharp 1 day share price decline of 15.7%. This comes alongside far stronger gains over the month, past 3 months, and past year.\nWith the stock closing at US$7.56 and a market value around US$1.67b, recent returns of 50.3% over the month and 82.2% over the past 3 months highlight how volatile sentiment around this cancer focused biopharmaceutical company can be.\nSee our latest analysis for SELLAS Life...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/assessing-sellas-life-sciences-group-sls-valuation-after-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/assessing-sellas-life-sciences-group-sls-valuation-after-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","SLS","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637356446","title":"SELLAS Life Sciences Group Down Nearly 19%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2637356446","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637356446?lang=en_us&edition=fundamental","pubTime":"2026-05-22 02:37","pubTimestamp":1779388620,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc.  is currently at $7.28, down $1.69 or 18.84%. --On pace for largest percent decrease since March 15, 2024, when it fell 29.03%. --Down 100% from its all-time closing high of $335363.30 on March 13, 2008. --Up 313.64% from 52 weeks ago , when it closed at $1.76. --Up 423.74% from its 52-week closing low of $1.39 on Dec. 2, 2025. --Down 22.41% at today's intraday low; largest intraday percent decrease since Jan. 6, 2026, when it fell as much as 27.6%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636601258","title":"SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2636601258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636601258?lang=en_us&edition=fundamental","pubTime":"2026-05-18 07:24","pubTimestamp":1779060289,"startTime":"0","endTime":"0","summary":"Earlier this week, SELLAS Life Sciences Group reported a first-quarter 2026 net loss of US$8.41 million while confirming its pivotal Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis.\nAlongside this, SELLAS strengthened its cash position to US$107.1 million, advanced its SLS009 candidate into a Phase 2 AML trial, and set up a US$150 million at-the-market equity program, underscoring a balance of late-stage and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-sls-nears-pivotal-aml-data-as-cash-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-sls-nears-pivotal-aml-data-as-cash-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","SLS","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197905650","title":"Stock Track | SELLAS Life Sciences Soars 5.21% Intraday on Investor Conference Announcements and Positive Growth Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1197905650","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197905650?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:51","pubTimestamp":1778773869,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712039","title":"SELLAS Life Sciences to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712039","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712039?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"NEW YORK, May  14, 2026  (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of n","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294873/0/en/SELLAS-Life-Sciences-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711421","title":"High Growth Tech Stocks in US for May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711421","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711421?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:08","pubTimestamp":1778756891,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/high-growth-tech-stocks-in-us-for-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/high-growth-tech-stocks-in-us-for-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","HLIT","SLS","RZLT","SLS.AU","BK7104","BK4020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229374","title":"Stocks to Watch: NextPower, Sellas, System1, Arteris","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229374","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229374?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:12","pubTimestamp":1778627520,"startTime":"0","endTime":"0","summary":"NextPower raised its sales outlook and said it plans to make an acquisition to support its entry into the power-conversion industry. The stock gained 11% to $138.91 in after-hours trading Tuesday.Sellas Life Sciences said one of its trials is close to being ready for a data review. The stock climbed 13% to $5.88 after the bell.System1 said its revenue halved during the first quarter. Shares slid 27% to $3.25 in late trade.Arteris raised its full-year revenue outlook. Shares rose 9% to $35.39.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU1983299162.USD","BK4585","LU0823414478.USD","LU0302445910.USD","AIP","BK4596","BK4097","LU1978683503.SGD","LU2294711713.HKD","LU0724618433.USD","SLS","LU2506951792.HKD","NXT","BK4139","BK4096","LU0728928796.USD","LU0823414551.USD","LU2275660780.HKD","BK4588","BK4077","LU0312595415.SGD","LU2298322129.HKD","LU2357125470.USD","LU0124384867.USD","LU2249611893.SGD","SST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635338226","title":"Sellas Life Sciences Shares Climb as Trial Nears Data Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2635338226","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635338226?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:17","pubTimestamp":1778624220,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences shares rose after the company said its Phase 3 trial is nearly ready for data review.The stock gained 13% to $5.91 in after-hours trading. Through the close, the stock was up 38% year to date.The late-stage clinical biopharmaceutical company's Phase 3 trial evaluating Galinpepimut-S as a treatment for leukemia requires 80 pre-specified events to lock the database and start analyzing it.As of May 11, 78 events had occurred, Sellas said. The company plans to provide an update when the 80th event happens.Sellas also said its loss widened to $8.4 million, or 5 cents a share, compared with a loss of $5.8 million, or 7 cents a share, in the year-ago quarter.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223360","title":"SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223360","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223360?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:05","pubTimestamp":1778619931,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.07) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52508843/sellas-life-sciences-gr-q1-eps-0-05-beats-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635983228","title":"SELLAS Life Sciences Group Q1 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2635983228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635983228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:44","pubTimestamp":1778618688,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group  reported a Q1 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.Two analysts polled by FactSet expected a loss of $0.06.Cash and cash equivalents were $107.1 million at the end of Q1, compared with $71.8 million at the end of Q4.Shares of the company rose more than 12% in after-hours activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","BK4139","BK7104","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240773","title":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240773","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240773?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:31","pubTimestamp":1778617888,"startTime":"0","endTime":"0","summary":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240584","title":"SELLAS Life Sciences Q1 net loss widens on higher expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240584?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:19","pubTimestamp":1778617157,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Q1 net loss widens on higher expensesOverviewUS biopharmaceutical developer's Q1 net loss widened amid higher operating expensesCompany ended Q1 with $107.1 mln in cash, plus $7.5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247562","title":"BRIEF-SELLAS Life Sciences Q1 Net Income USD -8.407 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247562","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247562?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616349,"startTime":"0","endTime":"0","summary":"BRIEF-SELLAS Life Sciences Q1 Net Income USD -8.407 Million\n\n\nMay 12 (Reuters) - SELLAS Life Sciences Q1 operating expenses USD 9.252 million.\n\nQ1 basic EPS USD -0.05\nQ1 operating income USD -9.252 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXEF60F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724735","title":"Sellas Life Sciences Q1 Net Income USD -8.407 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724735?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXEF60F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247111","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247111?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"-- Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes --. -- Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 Event --. -- $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises --. \"The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,\" said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. \"We are grateful for the ongoing commitment of the patients, caregivers, and investigators participating in the pivotal Phase 3 REGAL trial and we believe that the upcoming results, triggered by reaching the pre-speci","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242063","title":"Sellas Life Sciences Q1 FY26 net loss widens 44.63% to $8.41 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242063?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616165,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences posted a net loss of USD 8.41 million for the three months ended March 31, 2026, widening from USD 5.81 million a year earlier.Operating loss widened to USD 9.25 million from USD 6.06 million, as operating expenses climbed to USD 9.25 million from USD 6.06 million.Research and development expense rose to USD 5.13 million from USD 3.21 million, driven mainly by higher manufacturing costs tied to preparations for a potential BLA filing for GPS and higher clinical and regulatory consulting costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2vLswP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631050305","title":"Solstice Minerals Limited (SLS) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2631050305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631050305?lang=en_us&edition=fundamental","pubTime":"2026-04-30 12:35","pubTimestamp":1777523720,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Paul Howard CFA from Canaccord Genuity maintained a Buy rating on Solstice Minerals Limited, with a price target of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/solstice-minerals-limited-sls-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/solstice-minerals-limited-sls-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139","CFA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":0.1658},{"period":"1month","weight":0.8398},{"period":"3month","weight":0.7081},{"period":"6month","weight":4.8896},{"period":"1year","weight":4.3041},{"period":"ytd","weight":1.4058}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.030636},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01322},{"month":3,"riseRate":0.25,"avgChangeRate":-0.060862},{"month":4,"riseRate":0.5,"avgChangeRate":0.097703},{"month":5,"riseRate":0.75,"avgChangeRate":0.182109},{"month":6,"riseRate":0.25,"avgChangeRate":-0.184341},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.033023},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.058558},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.031827},{"month":10,"riseRate":0.363636,"avgChangeRate":0.051142},{"month":11,"riseRate":0.25,"avgChangeRate":-0.061889},{"month":12,"riseRate":0.25,"avgChangeRate":0.046982}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}